Northwestern Memorial Hospital files $96.5 million plan to upgrade ICU
Northwestern Memorial Hospital has asked state regulators to approve plans for a $96.5 million upgrade of its intensive care units.
Silver Cross Health System plans $20.6 million medical office building in Lemont
Silver Cross Health System has asked state regulators to approve a nearly $20.6 million plan for a new medical office building in Lemont.
Duly Surgery Center Westmont plans $6.2 million expansion
Duly Surgery Center Westmont has asked state regulators to approve a $6.2 million expansion of its facility.
Critics Say CDC Advisors’ Infection Control Guidance Isn’t Strong Enough
A CDC advisory committee voted unanimously on Friday to approve draft infection control guidelines, though some critics charge the recommendations don’t go far enough and ignore lessons from the COVID-19 pandemic. At the heart of the controversy is a new “air” category for pathogen transmission, and three levels of air precautions based on how transmissible […]
All Thumbs Up for OTC Birth Control Pill at FDA Advisory Meeting
In a unanimous vote, advisors to the FDA recommended the agency approve what could become the first-ever over the counter (OTC) birth control pill. All 17 members of the joint Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee said the widespread benefits of switching daily norgestrel tablets 0.075 mg (Opill) […]
Second RSV Vaccine for Older Adults Gets Thumbs Up From FDA Advisors
A panel of FDA’s outside advisors recommended the agency approve GSK’s respiratory syncytial virus (RSV) vaccine for older adults, a day after backing Pfizer’s RSV vaccine candidate for that same population. By votes of 12-0 on efficacy and 10-2 on safety, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) said the available data support […]
FDA Advisors Back Fecal Microbiome Treatment for Recurrent C. Diff
An FDA advisory board recommended the agency approve a fecal microbiota transfer (FMT) product for recurrent Clostridium difficile infections. By a vote of 13-4 on Thursday, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), said RBX2660 was effective for treating patients with recurrent C. diff infections who failed first-line antimicrobial therapy. Safety landed in […]